3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma, Ewing
1
Sarcoma
1
Rare Diseases
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasms, Bone Tissue
1
Neoplasms by Histologic Type
1
Neoplasms
1
Interventions
Doxorubicin
25
Ifosfamide
22
Radiotherapy
17
Etoposide
11
Vincristine
10
Cyclophosphamide
10
Filgrastim
8
Dactinomycin
8
Trabectedin
7
Chemotherapy, Adjuvant
5
pazopanib
4
Cisplatin
4
Topotecan
3
Radiation
3
Neoadjuvant Therapy
3
Irinotecan
3
Granulocyte Colony-Stimulating Factor
3
Dacarbazine
3
sargramostim
2
etoposide phosphate
2
eribulin
2
Observation
2
Methotrexate
2
Mesna
2
Imatinib Mesylate
2
Gemcitabine
2
Epirubicin
2
Docetaxel
2
Dexrazoxane
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Sarcoma
×
FANG vaccine
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts